Cover Image
市場調查報告書

C-C趨化素受體類型4 (C-C CKR-4/K5-5/CD194/CCR4):開發平台分析

C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 361648
出版日期 內容資訊 英文 45 Pages
訂單完成後即時交付
價格
Back to Top
C-C趨化素受體類型4 (C-C CKR-4/K5-5/CD194/CCR4):開發平台分析 C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Pipeline Review, H2 2016
出版日期: 2016年09月30日 內容資訊: 英文 45 Pages
簡介

本報告提供全球各國的C-C趨化素受體類型4 (C-CCKR-4或K5-5或CD194或CCR4)的開發中產品的開發情形相關分析,產品開發、上市的最新趨勢,及臨床實驗的各階段的產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊 ,為您概述為以下內容。

目錄

簡介

  • 分析範圍

C-C趨化素受體類型4 (C-C CKR-4/K5-5/CD194/CCR4)的概要

治療藥的開發情形

  • 臨床實驗的各階段
  • 各治療領域
  • 各症狀

開發中產品的概要

  • 後期階段的產品
  • 初期階段的產品

各企業開發中的治療藥

治療藥的評估

  • 單劑治療藥/並用治療藥的情況
  • 各作用機制
  • 各投藥法
  • 各分子類型

開發治療藥的企業

  • AstraZeneca Plc
  • ChemoCentryx, Inc.
  • Globavir Biosciences, Inc.
  • Kyowa Hakko Kirin
  • 小野藥品工業

藥物簡介

  • ZD-2098
    • 產品概要
    • 作用機制
    • 研究開發 (R&D)的發展情形
  • CCX-6239
  • E-0001163
  • GBV-3019
  • K-777
  • Mogamulizumab
  • 腫瘤、自體免疫疾病用CCR、CXCR拮抗用小分子

開發暫停的產品

開發中止的產品

值得注意的最新趨勢、新聞稿 (共15件)

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC0573TDB

Summary

Global Markets Direct's, 'C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Pipeline Review, H2 2016', provides in depth analysis on C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) targeted pipeline therapeutics.

The report provides comprehensive information on the C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

Certain sections in the report may be removed or altered based on the availability and relevance of data.

Updated report will be delivered in 48 hours of order confirmation.

Scope

  • The report provides a snapshot of the global therapeutic landscape for C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4)
  • The report reviews C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) targeted therapeutics and enlists all their major and minor projects
  • The report assesses C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) Overview
  • Therapeutics Development
    • C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Products under Development by Stage of Development
    • C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Products under Development by Therapy Area
    • C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Products under Development by Indication
  • C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Pipeline Products Glance
    • Late Stage Products
    • Early Stage Products
  • C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Products under Development by Companies
  • C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Therapeutics Assessment
    • Assessment by Monotherapy/Combination Products
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Companies Involved in Therapeutics Development
    • AstraZeneca Plc
    • ChemoCentryx, Inc.
    • Globavir Biosciences, Inc.
    • Kyowa Hakko Kirin Co., Ltd.
    • Ono Pharmaceutical Co., Ltd.
  • C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Drug Profiles
    • AZD-2098 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CCX-6239 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • E-0001163 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GBV-3019 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • K-777 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • mogamulizumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Antagonize CCR and CXCR for Oncology and Autoimmune Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Dormant Projects
  • C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Discontinued Products
  • C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Featured News & Press Releases
    • Jul 29, 2015: Kyowa Hakko Kirin and Bristol-Myers Squibb Announce Immuno-Oncology Clinical Collaboration Studying Mogamulizumab and Opdivo (nivolumab) in Advanced Solid Tumors in the U.S.
    • Dec 18, 2014: Approval for Additional Indication for Chemotherapy-Native CCR4-positive ATL of Mogamulizumab
    • Dec 10, 2014: Ono Pharmaceutical, Bristol-Myers Squibb and Kyowa Hakko Kirin Announce Immuno-Oncology Clinical Collaboration Studying Mogamulizumab in Advanced Solid Tumors
    • Sep 29, 2014: Pfizer And Kyowa Hakko Kirin To Collaborate On Immuno-Oncology Combination Study
    • Jun 30, 2014: Reapplication Seeking Approval for Additional Indication for ATL of Mogamulizumab
    • Mar 17, 2014: Approval for Additional Indication for PTCL and CTCL of Mogamulizumab
    • Feb 10, 2014: Change to Supplemental Application Seeking Approval of Additional Indication for Mogamulizumab
    • Jan 15, 2014: Addition of Japanese Sites for Pivotal Phase 3 Trial of Mogamulizumab in Patients with Cutaneous T-Cell Lymphoma
    • Jul 19, 2013: Application Seeking Approval for Additional Indication for ATL, PTCL and CTCL of Mogamulizumab
    • Dec 13, 2012: Kyowa Hakko Kirin Initiates Pivotal Phase III Trial Of Mogamulizumab In Patients With Cutaneous T-Cell Lymphoma In US
    • Dec 11, 2012: Kyowa Hakko Kirin Announces Presentation Of Phase II Clinical Trial Results Of Mogamulizumab At ASH Annual Meeting
    • Aug 23, 2012: Kyowa Hakko Kirin Initiates Pivotal Phase II Trial Of Mogamulizumab In Patients With Adult T-cell Leukemia-Lymphoma In US And Europe
    • Jul 19, 2012: Application Seeking Approval for Additional Indication for ATL, PTCL and CTCL of Mogamulizumab
    • May 29, 2012: Kyowa Hakko Kirin Launches POTELIGEO Injection In Japan
    • Mar 30, 2012: Kyowa Hakko Kirin Receives New Drug Application Approval For POTELIGEO Injection
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for, H2 2016
  • Number of Products under Development by Therapy Area, H2 2016
  • Number of Products under Development by Indication, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016
  • Assessment by Monotherapy/Combination Products, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Pipeline by AstraZeneca Plc, H2 2016
  • Pipeline by ChemoCentryx, Inc., H2 2016
  • Pipeline by Globavir Biosciences, Inc., H2 2016
  • Pipeline by Kyowa Hakko Kirin Co., Ltd., H2 2016
  • Pipeline by Ono Pharmaceutical Co., Ltd., H2 2016
  • Dormant Projects, H2 2016
  • Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for, H2 2016
  • Number of Products under Development by Therapy Area, H2 2016
  • Number of Products under Development by Top 10 Indication, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy/Combination Products, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
Back to Top